Three independent discounted-cash-flow-style models value ANI Pharmaceuticals, Inc. every trading day. 0 of 3 currently price ANIP above its market price.
| Free Cash Flow model | $-665.43 |
| Excess Profit model | $-646.71 |
| Residual Earnings model | $-6.56 |
| Dividend Discount model | — |
| Piotroski F-Score | 6 / 9 |
| Return on invested capital | +7.6% |
| Net debt / EBITDA | 3.0× |
| Gross margin | +100.0% |
| Revenue CAGR | +40.8% |
| Cash conversion | 2.4× |
| Dividend yield | — |
| Buyback yield | -3.8% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open ANIP in StockKitty